October 29, 2021 Go or go go? J&J’s cell therapy heads to the FDA November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
January 05, 2021 Hope versus experience in glioblastoma Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.